Medicure Inc. (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc. AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS). The Company is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD). The Company has completed Phase IIa stage of development for TARDOXAL. The Company is also developing Transdermal AGGRASTAT, a cure for acute cardiology. Transdermal AGGRASTAT is in preclinical-stage of development.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Exchange: CVE
- Symbol: MPH
- Previous Close: $0.00
- 50 Day Moving Average: $N/A
- 200 Day Moving Average: $N/A
- 52-Week Range: C$4.73 - C$10.67
- Trailing P/E Ratio: N/A
- P/E Growth: N/A
- Market Cap: $N/A
- Outstanding Shares: 15,532,000
Consensus Ratings for Medicure (CVE:MPH) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Medicure (CVE:MPH)
(Data available from 2/24/2015 forward)
|5/4/2016||M Partners||Reiterated Rating||Buy|
|1/12/2016||Mackie||Boost Price Target||Buy||C$8.00|
Earnings History for Medicure (CVE:MPH)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Medicure (CVE:MPH)
Current Year EPS Consensus Estimate: $0.32 EPS
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Medicure (CVE:MPH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Medicure (CVE:MPH)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/17/2016||Albert David Friesen||Director||Buy||1,100||C$5.55||C$6,105.00|
|3/16/2016||Graeme William Merchant||Insider||Buy||1,650||C$6.40||C$10,560.00|
|3/11/2016||Graeme William Merchant||Insider||Buy||1,500||C$6.30||C$9,450.00|
|3/8/2016||Graeme William Merchant||Insider||Sell||6,300||C$7.01||C$44,163.00|
|9/9/2015||Elliott International Capital||Insider||Sell||1,426,002||C$2.98||C$4,249,485.96|
|1/7/2015||Albert David Friesen||Director||Buy||2,900||C$2.01||C$5,829.00|
Latest Headlines for Medicure (CVE:MPH)
What is Medicure's stock symbol?
Medicure trades on the Canadian Venture Exchange (CVE) under the ticker symbol "MPH."
How do I buy Medicure stock?
Shares of Medicure and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
How much does a share of Medicure stock cost?
One share of Medicure stock can currently be purchased for approximately C$9.00.
Medicure (CVE:MPH) Chart for Friday, February, 24, 2017
Institutional Ownership ChartEarnings History ChartDividend History Chart